Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2020

Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms

Christian Di Buduo
Vittorio Abbonante
Francesco Moccia
Elisa Rumi
Daniela Pietra
Paolo Soprano
  • Fonction : Auteur
Dmitry Lim
Daniele Cattaneo
  • Fonction : Auteur
Alessandra Iurlo
Umberto Gianelli
Giovanni Barosi
Vittorio Rosti
Isabelle Plo
Mario Cazzola
Alessandra Balduini

Résumé

Abstract Approximately one-fourth of patients with essential thrombocythemia or primary myelofibrosis carry a somatic mutation of the calreticulin gene (CALR), the gene encoding for calreticulin. A 52-bp deletion (type I mutation) and a 5-bp insertion (type II mutation) are the most frequent genetic lesions. The mechanism(s) by which a CALR mutation leads to a myeloproliferative phenotype has been clarified only in part. We studied the interaction between calreticulin and store-operated calcium (Ca2+) entry (SOCE) machinery in megakaryocytes (Mks) from healthy individuals and from patients with CALR-mutated myeloproliferative neoplasms (MPNs). In Mks from healthy subjects, binding of recombinant human thrombopoietin to c-Mpl induced the activation of signal transducer and activator of transcription 5, AKT, and extracellular signal-regulated kinase 1/2, determining inositol triphosphate–dependent Ca2+ release from the endoplasmic reticulum (ER). This resulted in the dissociation of the ER protein 57 (ERp57)-mediated complex between calreticulin and stromal interaction molecule 1 (STIM1), a protein of the SOCE machinery that leads to Ca2+ mobilization. In Mks from patients with CALR-mutated MPNs, defective interactions between mutant calreticulin, ERp57, and STIM1 activated SOCE and generated spontaneous cytosolic Ca2+ flows. In turn, this resulted in abnormal Mk proliferation that was reverted using a specific SOCE inhibitor. In summary, the abnormal SOCE regulation of Ca2+ flows in Mks contributes to the pathophysiology of CALR-mutated MPNs. In perspective, SOCE may represent a new therapeutic target to counteract Mk proliferation and its clinical consequences in MPNs.

Dates et versions

hal-04430037 , version 1 (31-01-2024)

Identifiants

Citer

Christian Di Buduo, Vittorio Abbonante, Caroline Marty, Francesco Moccia, Elisa Rumi, et al.. Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135 (2), pp.133-144. ⟨10.1182/blood.2019001103⟩. ⟨hal-04430037⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More